Blood-brain barrier receptors and transporters: an insight on their function and how to exploit them through nanotechnology

References

• Rubin L, Staddibm J. The cell biology of the blood-brain barrier. Annu Rev Neurosci. 1999;22:11–28.
   PubMed Web of Science ®Google Scholar
• Persidsky Y, Ramirez S, Haorah J, et al. Blood-brain barrier: structural components and function under physiologic and pathologic conditions. J Neuroimmune Pharmacol. 2006;1(3):223–236.
   PubMed Web of Science ®Google Scholar
• Daneman R, Prat A. The blood-brain barrier. Cold Spring Harb Perspect Biol. 2015;7(1):a020412.
   PubMed Web of Science ®Google Scholar
• Brightman M, Reese T. Junctions between intimately apposed cell membranes in the vertebrate brain. J Cell Biol. 1969;40(3):648–677.
   PubMed Web of Science ®Google Scholar
• Serlin Y, Shelef I, Knyazer B, et al. Anatomy and physiology of the blood-brain barrier. Semin Cell Dev Biol. 2015;38:2–6.
   PubMed Web of Science ®Google Scholar
• Abbott N, Ronnback L, Hansson E. Astrocyte-endothelial interactions at the blood-brain barrier. Nat Rev Neurosci. 2006;7(1):41–53.
   PubMed Web of Science ®Google Scholar
• Moura R, Almeida A, Sarmento B. The role of non-endothelial cells on the penetration of nanoparticles through the blood brain barrier. Prog Neurobiol. 2017;159:39–49.
   PubMed Web of Science ®Google Scholar
• Jones A, Shusta E. Blood-brain barrier transport of therapeutics via receptor-mediation. Pharm Res. 2007;24(9):1759–1771.
   PubMed Web of Science ®Google Scholar
• Jefferies W, Brandor M, Hunt S, et al. Transferrin receptor on endothelium of brain capillaries. Nature. 1984;312:162–163.
   PubMed Web of Science ®Google Scholar
• Duffy K, Pardridge W. Blood-brain barrier transcytosis of insulin in developing rabbits. Brain Res. 1997;420:32–38.
   Web of Science ®Google Scholar
• Régina A, Morchoisne S, Borson N, et al. Factor(s) released by glucose-deprived astrocytes enhance glucose transporter expression and activity in rat brain endothelial cells. Biochem Biophys Acta. 2001;1540(3):233–242.
   PubMed Web of Science ®Google Scholar
• Xiao G, Gan L. Receptor-mediated endocytosis and brain delivery of therapeutic biologics. Int J Cell Biol. 2013;2013:7035–7045.
   Google Scholar
• Jain K. Nanobiotechnology-based strategies for crossing the blood-brain barrier. Nanomedicine (Lond). 2012;7:1225–1233.
   PubMed Web of Science ®Google Scholar
• Grabrucker A, Chabra R, Belletti D, et al. Nanoparticles as blood–brain barrier permeable CNS targeted drug delivery systems. Top Med Chem. 2014;10:71–90.
   Google Scholar
• Saraiva C, Praça C, Ferreira R, et al. Nanoparticle-mediated brain drug delivery: overcoming blood–brain barrier to treat neurodegenerative diseases. J Control Release. 2016;235:34–47.
   PubMed Web of Science ®Google Scholar
• Campos-Bedolla R, Walter F, Veszelka S, et al. Role of the blood-brain barrier in the nutrition of the central nervous system. Arch Med Res. 2014;45:610–638.
   PubMed Web of Science ®Google Scholar
• Abbott N. Blood-brain barrier structure and function and the challenges for CNS drug delivery. J Inherit Metab Dis. 2013;36(3):437–449.
   PubMed Web of Science ®Google Scholar
• Haddad-Tovólli R, Dragano N, Ramalho A, et al. Development and function of the blood-brain barrier in the context of metabolic control. Front Neurosci. 2017;11:224.
   PubMed Web of Science ®Google Scholar
• Simard M, Nedergaard M. The neurobiology of glia in the context of water and ion homeostasis. Neuroscience. 2004;129:877–896.
   PubMed Web of Science ®Google Scholar
• Broux B, Gowing E, Prat A. Glial regulation of the blood-brain barrier in health and disease. Semin Immunopathol. 2015;37:577–590.
   PubMed Web of Science ®Google Scholar
• Tao-Cheng J, Brightman M. Development of membrane interactions between brain endothelial cells and astrocytes in vitro. Int J Dev Neurosci. 1988;6:25–37.
   PubMed Web of Science ®Google Scholar
• Nakagawa S, Deli M, Nakao S, et al. Pericytes from brain microvessels strengthen the barrier integrity in primary cultures of rat brain endothelial cells. Cell Mol Neurobiol. 2007;27(6):687–694.
   PubMed Web of Science ®Google Scholar
• Armulik A, Genové G, Mae M, et al. Pericytes regulate the blood–brain barrier. Nature. 2010;468:557–561.
   PubMed Web of Science ®Google Scholar
• Obermeier B, Verma A, Ransohoff R. The blood-brain barrier. Handb Clin Neurol. 2016;133:39–59.
   PubMedGoogle Scholar
• Luissint A, Artus C, Glacial F, et al. Tight junctions at the blood brain barrier: physiological architecture and disease-associated dysregulation. Fluids Barriers CNS. 2012;9(1):23.
   PubMedGoogle Scholar
• Stamatovic S, Keep R, Andjelkovic A. Brain endothelial cell-cell junctions: how to “open” the blood brain barrier. Curr Neuropharmacol. 2008;6(3):179–192.
   PubMed Web of Science ®Google Scholar
• Wolburg H, Lippoldt A. Tight junctions of the blood–brain barrier: development, composition and regulation. Vascul Pharmacol. 2002;38(6):323–337.
   PubMed Web of Science ®Google Scholar
• Dauchy S, Dutheil F, Weaver R, et al. ABC transporters, cytochromes P450 and their main transcription factors: expression at the human blood-brain barrier. J Neurochem. 2008;107:1518–1528.
   PubMed Web of Science ®Google Scholar
• Begley D. ABC transporters and the blood-brain barrier. Curr Pharm Des. 2004;10(12):1295–1312.
   PubMed Web of Science ®Google Scholar
• Meyer R, Gehlhaus M, Knoth R, et al. Expression and function of cytochrome p450 in brain drug metabolism. Curr Drug Metab. 2007;8(4):297–306.
   PubMed Web of Science ®Google Scholar
• Mahringer A, Frickler G. ABC transporters at the blood-brain barrier. Expert Opin Drug Metabol Toxicol. 2016;12(5):499–508.
   PubMed Web of Science ®Google Scholar
• Barar J, Rafi M, Pourseif M, et al. Blood-brain barrier transport machineries and targeted therapy of brain diseases. Bioimpacts. 2016;6(4):225–248.
   PubMed Web of Science ®Google Scholar
• Lajoie J, Shusta E. Targeting receptor-mediated transport for delivery of biologics across the blood-brain barrier. Annu Rev Pharmacol Toxicol. 2015;55:613–631.
   PubMed Web of Science ®Google Scholar
• Abbott N, Patabendige A, Dolman D, et al. Structure and function of the blood–brain barrier. Neurobiol Dis. 2010;37(1):13–25.
   PubMed Web of Science ®Google Scholar
• Wang Y, Lui P, Li J. Receptor-mediated therapeutic transport across the blood-brain barrier. Immunotherapy. 2009;1(6):983–993.
   PubMed Web of Science ®Google Scholar
• Tamai I, Tsuji A. Transporter-mediated permeation of drugs across the blood-brain barrier. J Pharm Sci. 2000;89(11):1371–1388.
   PubMed Web of Science ®Google Scholar
• Cheng Y, Zak O, Aisen P, et al. Structure of the human transferrin receptor-transferrin complex. Cell. 2004;116(4):565–576.
   PubMed Web of Science ®Google Scholar
• Moos T, Morgan E. Transferrin and transferrin receptor function in brain barrier systems. Cell Mol Neurobiol. 2000;20(1):77–95.
   PubMed Web of Science ®Google Scholar
• Leibman A, Aisen P. Distribution of iron between the binding-sites of transferrin in serum—methods and results in normal human subjects. Blood. 1979;53(6):1058–1065.
   PubMed Web of Science ®Google Scholar
• Omary M, Trowbridge I. Biosynthesis of the human serum transferrin receptor in cultured-cells. J Biol Chem. 1981;256(24):12888–12892.
   PubMed Web of Science ®Google Scholar
• Qian Z, Li H, Sun H, et al. Targeted drug delivery via the transferrin receptor-mediated endocytosis pathway. Pharmacol Rev. 2002;54(4):561–587.
   PubMed Web of Science ®Google Scholar
• Inoue T, Cavanaugh P, Steck P, et al. Differences in transferrin response and numbers of transferrin receptors in rat and human mammary carcinoma lines of different metastatic potentials. J Cell Physiol. 1993;156(1):212–217.
   PubMed Web of Science ®Google Scholar
• Kawabata H, Yang R, Hirama T, et al. Molecular cloning of transferrin receptor 2—A new member of the transferrin receptor-like family. J Biol Chem. 1999;274(30):20826–20832.
   PubMed Web of Science ®Google Scholar
• Kawabata H, Nakamaki T, Ikonomi P, et al. Expression of transferrin receptor 2 in normal and neoplastic hematopoietic cells. Blood. 2001;98(9):2714–2719.
   PubMed Web of Science ®Google Scholar
• Mills E, Dong X-P, Wang F, et al. Mechanisms of brain iron transport: insight into neurodegeneration and CNS disorders. Future Med Chem. 2010;2(1):51.
   PubMed Web of Science ®Google Scholar
• Dautry-Varsat A, Ciechanover A, Lodish H. pH and the recycling of transferrin during receptor-mediated endocytosis. Proc Natl Acad Sci U S A. 1983;80(8):2258–2262.
   PubMed Web of Science ®Google Scholar
• Bickel U, Yosikawa T, Pardridge W. Delivery of peptides and proteins through the blood-brain barrier. Adv Drug Deliv Rev. 2001;46(1–3):247–279.
   PubMed Web of Science ®Google Scholar
• Roberts R, Sandra A, Siek G, et al. Studies of the mechanism of iron transport across the blood-brain barrier. Ann Neurol. 1992;32(Suppl):S43–50.
   PubMed Web of Science ®Google Scholar
• Duck K, Connor J. Iron uptake and transport across physiological barriers. Biometals. 2016;29:573–591.
   PubMed Web of Science ®Google Scholar
• Johnsen K, Burkhart A, Melander F, et al. Targeting transferrin receptors at the blood-brain barrier improves the uptake of immunoliposomes and subsequent cargo transport into the brain parenchyma. Sci Rep. 2017;7(1). DOI:10.1038/s41598-017-11220-
   Web of Science ®Google Scholar
• Lee H, Engelhardt B, Lesley J, et al. Targeting rat anti-mouse transferrin receptor monoclonal antibodies through blood-brain barrier in mouse. J Pharmacol Exp Ther. 2000;292(3):1048–1052.
   PubMed Web of Science ®Google Scholar
• Friden P, Olson T, Obar R, et al. Characterization, receptor mapping and blood-brain barrier transcytosis of antibodies to the human transferrin receptor. J Pharmacol Exp Ther. 1996;278(3):1491–1498.
   PubMed Web of Science ®Google Scholar
• Adamo M, Raizada M, LeRoith D. Insulin and insulin-like growth factor receptors in the nervous system. Mol Neurobiol. 1989;3(1–2):71–100.
   PubMed Web of Science ®Google Scholar
• Masnikosa R, Baricevic I, Jones D, et al. Characterisation of insulin-like growth factor receptors and insulin receptors in the human placenta using lectin affinity methods. Growth Horm IGF Res. 2006;16(3):174–184.
   PubMed Web of Science ®Google Scholar
• Plum L, Schubert M, Bruning J. The role of insulin receptor signaling in the brain. Trends Endocrinol Metab. 2005;16(2):59–65.
   PubMed Web of Science ®Google Scholar
• De Meyts P, Whittaker J. Structural biology of insulin and IGF1 receptors: implications for drug design. Nat Rev Drug Discov. 2002;1(10):769–783.
   PubMed Web of Science ®Google Scholar
• Fu Z, Gilbert E, Liu D. Regulation of insulin synthesis and secretion and pancreatic beta-cell dysfunction in diabetes. Curr Diabetes Rev. 2013;9(1):25–53.
   PubMedGoogle Scholar
• Rhea E, Rask-Madsen C, Banks W. Insulin transport across the blood-brain barrier can occur independently of the insulin receptor. J Physiol. 2018;596(19):4753–4765.
   PubMed Web of Science ®Google Scholar
• Boado R, Zhang Y, Zhang Y, et al. Humanization of anti-human insulin receptor antibody for drug targeting across the human blood-brain barrier. Biotechnol Bioeng. 2007;96(2):381–391.
   PubMed Web of Science ®Google Scholar
• Boado R, Hui E, Lu J, et al. Blood-brain barrier molecular trojan horse enables imaging of brain uptake of radioiodinated recombinant protein in the rhesus monkey. Bioconjug Chem. 2013;24(10):1741–1749.
   PubMed Web of Science ®Google Scholar
• Ohshima-Hosoyama S, Simmons H, Goecks N, et al. A monoclonal antibody–GDNF fusion protein is not neuroprotective and is associated with proliferative pancreatic lesions in Parkinsonian monkeys. PLoS One. 2012;7(6):e39036.
   PubMed Web of Science ®Google Scholar
• Defesche J. Lowdensity lipoprotein receptor - its structure, function, and mutations. Semin Vasc Med. 2004;4(1):5–11.
   PubMedGoogle Scholar
• Sudhof T, Goldstein J, Brown M, et al. The LDL receptor gene: a mosaic of exons shared with different proteins. Science. 1985;228(4701):815–822.
   PubMed Web of Science ®Google Scholar
• Zhao Y, Li D, Zhao J, et al. The role of the low-density lipoprotein receptor-related protein 1 (LRP-1) in regulating blood-brain barrier integrity. Rev Neurosci. 2016;27(6):623–634.
   PubMed Web of Science ®Google Scholar
• Gent J, Braakman I. Low-density lipoprotein receptor structure and folding. Cell Mol Life Sci. 2004;61(19–20):2461–2470.
   PubMed Web of Science ®Google Scholar
• Wang P, Xue Y, Shang X, et al. Diphtheria toxin mutant CRM197-mediated transcytosis across blood-brain barrier in vitro. Cell Mol Neurobiol. 2010;30(5):717–725.
   PubMed Web of Science ®Google Scholar
• Wang P, Liu Y, Shang X, et al. CRM197-induced blood-brain barrier permeability increase is mediated by upregulation of caveolin-1 protein. J Mol Neurosci. 2011;43(3):485–492.
   PubMed Web of Science ®Google Scholar
• Okamoto T, Schlegel A, Scherer P, et al. Caveolin, a family of scaffolding proteins for organizing ‘preassembled signaling complex’ at the plasma membrane. J Biol Chem. 1998;273(10):5419–5422.
   PubMed Web of Science ®Google Scholar
• Bathori G, Cervenak L, Karadi I. Caveolae–an alternative endocytotic pathway for targeted drug delivery. Crit Rev Ther Drug Carrier Syst. 2004;21(2):67–95.
   PubMed Web of Science ®Google Scholar
• Dehouck B, Dehouck M, Fruchart J, et al. Upregulation of the low density lipoprotein receptor at the blood-brain barrier: intercommunications between brain capillary endothelial cells and astrocytes. J Cell Biol. 1994;126(2):465–473.
   PubMed Web of Science ®Google Scholar
• Sorrentino N, D’Orsi L, Sambri I, et al. A highly secreted sulphamidase engineered to cross the blood-brain barrier corrects brain lesions of mice with mucopolysaccharidoses type IIIA. EMBO Mol Med. 2013;5(5):675–690.
   PubMed Web of Science ®Google Scholar
• Wang D, El-Amouri S, Dai M, et al. Engineering a lysosomal enzyme with a derivative of receptor-binding domain of apoE enables delivery across the blood-brain barrier. Proc Natl Acad Sci USA. 2013;110(8):2999–3004.
   PubMed Web of Science ®Google Scholar
• Régina A, Demeule M, Ché C, et al. Antitumour activity of ANG1005, a conjugate between paclitaxel and the new brain delivery vector Angiopep-2. Br J Pharmacol. 2008;155(2):185–197.
   PubMed Web of Science ®Google Scholar
• Deng D, Xu C, Sun P, et al. Crystal structure of the human glucose transporter GLUT1. Nature. 2014;510:121–125.
   PubMed Web of Science ®Google Scholar
• Patching S. Glucose transporters at the blood-brain barrier: function, regulation and gateways for drug delivery. Mol Neurobiol. 2017;54(2):1046–1077.
   PubMed Web of Science ®Google Scholar
• McAllister M, Krizanac-Bengez L, Macchia F, et al. Mechanisms of glucose transport at the blood-brain barrier: an in vitro study. Brain Res. 2001;904(1):20–30.
   PubMed Web of Science ®Google Scholar
• Farrell C, Pardridge W. Blood-brain barrier glucose transporter is asymmetrically distributed on brain capillary endothelial lumenal and ablumenal membranes: an electron microscopic immunogold study. Proc Natl Acad Sci U S A. 1991;88(13):5779–5783.
   PubMed Web of Science ®Google Scholar
• Devraj K, Klinger M, Myers R, et al. GLUT-1 glucose transporters in the blood-brain barrier: differential phosphorylation. J Neurosci Res. 2011;89(12):1913–1925.
   PubMed Web of Science ®Google Scholar
• Joost H, Thorens B. The extended GLUT-family of sugar/polyol transport facilitators: nomenclature, sequence characteristics, and potential function of its novel members. Mol Membr Biol. 2001;18(4):247–256.
   PubMed Web of Science ®Google Scholar
• Bhattacharyya S, Kattel K, Kim F. Modulating the glucose transport by engineering gold nanoparticles. J Nanomed Biotherapeutic Discovery. 2016;6:141.
   Google Scholar
• Prokop J, Duff R, Ball H, et al. Leptin and leptin receptor: analysis of a structure to function relationship in interaction and evolution from humans to fish. Peptides. 2012;38(2):326–336.
   PubMed Web of Science ®Google Scholar
• Bacart J, Leloire A, Levoye A, et al. Evidence for leptin receptor isoforms heteromerization at the cell surface. FEBS Lett. 2010;584(11):2213–2217.
   PubMed Web of Science ®Google Scholar
• Maffei M, Fei H, Lee G, et al. Increased expression in adipocytes of ob RNA in mice with lesions of the hypothalamus and with mutations at the db locus. Proc Natl Acad Sci U S A. 1995;92(15):6957–6960.
   PubMed Web of Science ®Google Scholar
• Schwartz M, Seeley R, Campfield L, et al. Identification of targets of leptin action in rat hypothalamus. J Clin Invest. 1996;98(5):1101–1106.
   PubMed Web of Science ®Google Scholar
• Sierra-Honigmann M, Nath A, Murakami C, et al. Biological action of leptin as an angiogenic factor. Science. 1998;281(5383):1683–1686.
   PubMed Web of Science ®Google Scholar
• Boado R, Golden P, Levin N, et al. Up-regulation of blood-brain barrier short-form leptin receptor gene products in rats fed a high fat diet. J Neurochem. 1998;71(4):1761–1764.
   PubMed Web of Science ®Google Scholar
• Amiri Darban S, Nikoofal-Sahlabadi S, Amiri N, et al. Targeting the leptin receptor: to evaluate therapeutic efficacy and anti-tumor effects of Doxil, in vitro and in vivo in mice bearing C26 colon carcinoma tumor. Colloids Surf B Biointerfaces. 2018;164:107–115.
   PubMed Web of Science ®Google Scholar
• Unwin N. Refined structure of the nicotinic acetylcholine receptor at 4A resolution. J Mol Biol. 2005;346(4):967–989.
   PubMed Web of Science ®Google Scholar
• Albuquerque E, Pereira E, Alkondon M, et al. Mammalian nicotinic acetylcholine receptors: from structure to function. Physiol Rev. 2009;89(1):73–120.
   PubMed Web of Science ®Google Scholar
• Alkondon M, Albuquerque E. The nicotinic acetylcholine receptor subtypes and their function in the hippocampus and cerebral cortex. Prog Brain Res. 2004;145:109–120.
   PubMed Web of Science ®Google Scholar
• Dineley K, Pandya A, Yakel J. Nicotinic ACh receptors as therapeutic targets in CNS disorders. Trends Pharmacol Sci. 2015;36(2):96–108.
   PubMed Web of Science ®Google Scholar
• Hueffer K, Khatri S, Rideout S, et al. Rabies virus modifies host behaviour through a snake-toxin like region of its glycoprotein that inhibits neurotransmitter receptors in the CNS. Sci Rep. 2017;7(1):12818.
   PubMed Web of Science ®Google Scholar
• Wei X, Zhan C, Shen Q, et al. A D-peptide ligand of nicotine acetylcholine receptors for brain-targeted drug delivery. Angew Chem Int Ed Engl. 2015;54(10):3023–3027.
   PubMed Web of Science ®Google Scholar
• Vinante F, Rigo A. Heparin-binding epidermal growth factor-like growth factor/diphtheria toxin receptor in normal and neoplastic hematopoiesis. Toxins (Basel). 2013;5(6):1180–1201.
   PubMed Web of Science ®Google Scholar
• Gaillard P, Brink A, de Boer A. Diphtheria toxin receptor-targeted brain drug delivery. Int Congr Ser. 2005;1277:185–198.
   Google Scholar
• Gabathuler R. Approaches to transport therapeutic drugs across the blood–brain barrier to treatbrain diseases. Neurobiol Dis. 2010;37(1):48–57.
   PubMed Web of Science ®Google Scholar
• Prabhudas M, Bowdish D, Drickamer K, et al. Standardizing scavenger receptor nomenclature. J Immunol. 2014;192(5):1997–2006.
   PubMed Web of Science ®Google Scholar
• Zani I, Stephen S, Mughal N, et al. Scavenger receptor structure and function in health and disease. Cells. 2015;4(2):178–201.
   PubMed Web of Science ®Google Scholar
• Chen Y, Wang X, Ben J, et al. The di-leucine motif contributes to class a scavenger receptor-mediated internalization of acetylated lipoproteins. Arterioscler Thromb Vasc Biol. 2006;26(6):1317–1322.
   PubMed Web of Science ®Google Scholar
• Srimanee A, Regberg J, Hällbrink M, et al. Role of scavenger receptors in peptide-based delivery of plasmid DNA across a blood-brain barrier model. Int J Pharm. 2016;500(1–2):128–135.
   PubMed Web of Science ®Google Scholar
• Li J, Paragas N, Ned R, et al. Scara5 is a ferritin receptor mediating non-transferrin iron delivery. Dev Cell. 2009;16(1):35–46.
   PubMed Web of Science ®Google Scholar
• Lushchak V. Glutathione homeostasis and functions: potential targets for medical interventions. J Amino Acids. 2012;2012. DOI:10.1155/2012/736837.
   PubMedGoogle Scholar
• Kannan R, Chakrabarti R, Tang D, et al. GSH transport in human cerebrovascular endothelial cells and human astrocytes: evidence for luminal localization of Na+-dependent GSH transport in HCEC. Brain Res. 2000;852(2):374–382.
   PubMed Web of Science ®Google Scholar
• Kannan R, Mittuer A, Bao Y, et al. GSH transport in immortalized mouse brain endothelial cells: evidencefor apical localization of a sodium-dependentGSH transporter. J Neurochem. 1999;73(1):390–399.
   PubMed Web of Science ®Google Scholar
• Gaillard P, Appeldoorn C, Dorland R, et al. Pharmacokinetics, brain delivery, and efficacy in brain tumor-bearing mice of glutathione pegylated liposomal doxorubicin (2B3-101). PLoS One. 2014;9(1):e82331.
   PubMed Web of Science ®Google Scholar
• Kuo T, Baker K, Yoshida M, et al. Neonatal Fc receptor: from immunity to therapeutics. J Clin Immunol. 2010;30(6):777–789.
   PubMed Web of Science ®Google Scholar
• Roopenian D, Akilesh S. FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol. 2007;7(9):715–725.
   PubMed Web of Science ®Google Scholar
• Martins J, Kennedy P, Santos H, et al. A comprehensive review of the neonatal Fc receptor and its application in drug delivery. Pharmacol Ther. 2016;161:22–39.
   PubMed Web of Science ®Google Scholar
• Schlachetzki F, Zhu C, Pardridge W. Expression of the neonatal Fc receptor (FcRn) at the blood-brain barrier. J Neurochem. 2002;81(1):203–206.
   PubMed Web of Science ®Google Scholar
• Cooper P, Ciambrone G, Kliwinski C, et al. Efflux of monoclonal antibodies from rat brain by neonatal Fc receptor, FcRn. Brain Res. 2013;1534:13–21.
   PubMed Web of Science ®Google Scholar
• Vasiliou V, Vasiliou K, Nebert D. Human ATP-binding cassette (ABC) transporter family. Hum Genomics. 2009;3(3):281–290.
   PubMedGoogle Scholar
• Doran A, Obach R, Smith B, et al. The impact of P-glycoprotein on the disposition of drugs targeted for indications of the central nervous system: evaluation using the MDR1A/1B knockout mouse model. Drug Metab Dispos. 2005;33(1):165–174.
   PubMed Web of Science ®Google Scholar
• Mahringer A, Ott M, Reinold I, et al. The ABC of the blood-brain barrier - regulation of drug efflux pumps. Curr Pharm Des. 2011;17(26):2762–2770.
   PubMed Web of Science ®Google Scholar
• Zhou S. Structure, function and regulation of P-glycoprotein andits clinical relevance in drug disposition. Xenobiotica. 2008;38:7–8.
   Web of Science ®Google Scholar
• Juliano R, Ling V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta. 1976;455(1):152–162.
   PubMed Web of Science ®Google Scholar
• Cordon-Cardo C, O’Brien J, Casais D, et al. Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc Natl Acad Sci USA. 1989;86(2):695–698.
   PubMed Web of Science ®Google Scholar
• Beaulieu E, Demeule M, Ghitescu L, et al. P-glycoprotein is strongly expressed in the luminal membranes of the endothelium of blood vessels in the brain. Biochem J. 1997;326(Pt. 2):539–544.
   PubMed Web of Science ®Google Scholar
• Solazzo M, Fantappié O, Lasagna N, et al. P-gp localization in mitochondria and its functional characterization in multiple drug-resistant cell lines. Exp Cell Res. 2006;312(20):4070–4078.
   PubMed Web of Science ®Google Scholar
• Bendayan R, Lee G, Bendayan M. Functional expression and localization of P-glycoprotein at the blood brain barrier. Microsc Res Tech. 2002;57(5):365–380.
   PubMed Web of Science ®Google Scholar
• Rosenberg M, Bikadi Z, Chan J, et al. The human breast cancer resistance protein (BCRP/ABCG2) shows conformational changes with mitoxantrone. Structure. 2010;18(4):482–493.
   PubMed Web of Science ®Google Scholar
• Hartz A, Bauer B. ABC transporters in the CNS - an inventory. Curr Pharm Biotechnol. 2011;12(4):656–673.
   PubMed Web of Science ®Google Scholar
• Bleau A, Huse J, Holland E. The ABCG2 resistance network of glioblastoma. Cell Cycle. 2009;8(18):2936–2944.
   PubMed Web of Science ®Google Scholar
• Ronaldson P, Bendayan M, Gingras D, et al. Cellular localization and functional expression of P-glycoprotein in rat astrocyte cultures. J Neurochem. 2004;89(3):788–800.
   PubMed Web of Science ®Google Scholar
• Gomes M, Kennedy P, Martins S, et al. Delivery of siRNA silencing P-gp in peptide-functionalized nanoparticles causes efflux modulation at the blood-brain barrier. Nanomedicine (Lond). 2017;12(12). DOI:10.2217/nnm-2017-0023
   PubMed Web of Science ®Google Scholar
• Yamazaki Y, Kanekiyo T. Blood-brain barrier dysfunction and the pathogenesis of Alzheimer’s disease. Int J Mol Sci. 2017;18(9):E1965.
   PubMed Web of Science ®Google Scholar
• Tomimoto H, Akiguchi I, Suenaga T, et al. Alterations ofthe blood-brain barrier and glial cells in white-matter lesions in cerebrovascular and Alzheimer’s diseasepatients. Stroke. 1996;27(11):2069–2074.
   PubMed Web of Science ®Google Scholar
• Carrano A, Hoozemans J, van der Vies S, et al. Neuroinflammation and blood-brain barrier changes in capillary amyloid angiopathy. Neurodegener Dis. 2012;10(1–4):329–331.
   PubMed Web of Science ®Google Scholar
• Kalaria R. The blood-brain barrier and cerebrovascular pathology in Alzheimer’s disease. Ann N Y Acad Sci. 1999;893:113–125.
   PubMed Web of Science ®Google Scholar
• Deane R, Wu Z, Sagare A, et al. LRP/amyloid beta-peptide interaction mediates differential brain efflux of Abeta isoforms. Neuron. 2004;43(3):333–344.
   PubMed Web of Science ®Google Scholar
• Shibata M, Yamada S, Kumar S, et al. Clearance of Alzheimer’s amyloid-ss(1–40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. J Clin Invest. 2000;106(12):1489–1499.
   PubMed Web of Science ®Google Scholar
• Coraci I, Husemann J, Berman J, et al. CD36, a class B scavenger receptor, is expressed on microglia in Alzheimer’s disease brains and can mediate production of reactive oxygen species in response to β-amyloid fibrils. Am J Pathol. 2002;160(1):101–112.
   PubMed Web of Science ®Google Scholar
• Zhang H, Su Y, Zhou W, et al. Activated scavenger receptor a promotes glial internalization of Aβ. PLoS One. 2014;9(4):e94197.
   PubMed Web of Science ®Google Scholar
• Vogelgesang S, Cascorbi I, Schoreder E, et al. Deposition of Alzheimer’s beta-amyloid is inversely correlated with P-glycoprotein expression in the brains of elderly non-demented humans. Phahrmacogenetics. 2002;12(7):535–541.
   PubMedGoogle Scholar
• Chen X, Lan X, Roche I, et al. Caffeine protects against MPTP induced blood-brain barrier dysfunction in mouse striatum. J Neurochem. 2008;107(4):1147–1157.
   PubMed Web of Science ®Google Scholar
• Kortekaas R, Leenders K, van Oostrem J, et al. Blood-brain barrier dysfunction in parkinsonian midbrain in vivo. Ann Neurol. 2005;57(2):176–179.
   PubMed Web of Science ®Google Scholar
• Gu X-L, Long C-X, Sun L, et al. Astrocytic expression of Parkinson’s disease-related A53T α-synuclein causes neurodegeneration in mice. Mol Brain. 2010;3:12.
   PubMed Web of Science ®Google Scholar
• Ayton S, Lei P, Mclean C, et al. Transferrin protects against Parkinsonian neurotoxicity and is deficient in Parkinson’s substantia nigra. Signal Transduct Target Ther. 2016;1:16015.
   PubMed Web of Science ®Google Scholar
• Van Tellingen O, Yetkin-Arik B, de Gooijer M, et al. Overcoming the blood-brain tumor barrier for effective glioblastoma treatment. Drug Resist Updat. 2015;19:1–12.
   PubMed Web of Science ®Google Scholar
• Aronica E, Gorter J, Redeker S, et al. Localization of breast cancer resistance protein (BCRP) in microvessel endothelium of human control and epileptic brain. Epilepsia. 2005;46(6):849–857.
   PubMed Web of Science ®Google Scholar
• Choudhury H, Pandey M, Chin P, et al. Transferrin receptors-targeting nanocarriers for efficient targeted delivery and transcytosis of drugs into the brain tumors: a review of recent advancements and emerging trends. Drug Deliv Transl Res. 2018;8(5):1545–1563.
   PubMed Web of Science ®Google Scholar
• Gong Y, Ma Y, Sinyuk M, et al. Insulin-mediated signaling promotes proliferation and survival of glioblastoma through Akt activation. Neuro Oncol. 2016;18(1):48–57.
   PubMed Web of Science ®Google Scholar
• Kang E, Major S, Jorks D, et al. Blood-brain barrier opening to large molecules does not imply blood-brain barrier opening to small ions. Neurobiol Dis. 2013;52:204–218.
   PubMed Web of Science ®Google Scholar
• Haley M, Lawrence C. The blood–brain barrier after stroke: structural studies and the role of transcytotic vesicle. J Cereb Blood Flow Metab. 2017;37(2):456–470.
   PubMed Web of Science ®Google Scholar
• McCall A, Van Bueren A, Nipper V, et al. Forebrain ischemia increases GLUT1 protein in brain microvessels and parenchyma. J Cereb Blood Flow Metab. 1996;16(1):69–76.
   PubMed Web of Science ®Google Scholar
• Shah K, Boreddy P, Abbruscato T. Nicotine pre-exposure reduces stroke-induced glucose transporter-1 activity at the blood–brain barrier in mice. Fluids Barriers CNS. 2015;12:10.
   PubMed Web of Science ®Google Scholar
• Ueno M, Wu B, Nakagawa T, et al. The expression of LDL receptor in vessels with blood-brain barrier impairment in a stroke-prone hypertensive model. Histochem Cell Biol. 2010;133(6):669–676.
   PubMed Web of Science ®Google Scholar
• Waubant E. Biomarkers indicative of blood-brain barrier disruption in multiple sclerosis. Dis Markers. 2006;22(4):235–244.
   PubMed Web of Science ®Google Scholar
• Updahyay R. Drug delivery systems, CNS protection, and the blood brain barrier. Biomed Res Int. 2014;2014:869269.
   PubMed Web of Science ®Google Scholar
• Saini R, Saini S, Sharma S. Nanotechnology: the Future Medicine. J Cutan Aesthet Surg. 2010;3(1):32–33.
   PubMedGoogle Scholar
• Zhang T, Li W, Meng G, et al. Strategies for transporting nanoparticles across the blood-brain barrier. Biomater Sci. 2016;4(2):219–229.
   PubMed Web of Science ®Google Scholar
• Kim B, Rutka J, Chan W. Nanomedicine. N Engl J Med. 2010;363(25):2434–2443.
   PubMed Web of Science ®Google Scholar
• Zhou Y, Peng Z, Seven E, et al. Crossing the blood-brain barrier with nanoparticles. J Control Release. 2018;270(28):290–303.
   PubMed Web of Science ®Google Scholar
• Mout R, Moyano D, Rana S, et al. Surface functionalization of nanoparticles for nanomedicine. Chem Soc Rev. 2012;41(7):2539–2544.
   PubMed Web of Science ®Google Scholar
• Hoffman A. The origins and evolution of “controlled” drug delivery systems. J Control Release. 2008;132(3):153–163.
   PubMed Web of Science ®Google Scholar
• Tang H, Z H, Ye H, et al. Receptor-mediated endocytosis of nanoparticles: roles of shapes,orientations, and rotations of nanoparticles. J Phys Chem B. 2018;122(1):171–180.
   PubMed Web of Science ®Google Scholar
• Vácha R, Martinez-Veracoechea F, Frenkel D. Receptor-mediated endocytosis of nanoparticles of various shapes. Nano Lett. 2011;11(12):5391–5395.
   PubMed Web of Science ®Google Scholar
• Meng X, Size Limit LX. Energy analysis of nanoparticles during wrapping process by membrane. Nanomaterials (Basel). 2018;8(11):899.
   Google Scholar
• Grabrucker A, Chhabra R, Belletti D, et al. Topics in Medicinal Chemistry. Berlin: Springer; 2013.
   Google Scholar
• Dilnawaz F, Sahoo S. Therapeutic approaches of magnetic nanoparticles for the central nervous system. Drug Discov Today. 2015;20(10):1256–1264.
   PubMed Web of Science ®Google Scholar
• Dixit S, Novak T, Miller K, et al. Transferrin receptor-targeted theranostic gold nanoparticles for photosensitizer delivery in brain tumors. Nanoscale. 2015;7(5):1782–1790.
   PubMed Web of Science ®Google Scholar
• Ulbrich K, Hekmatara T, Herbert E, et al. Transferrin- and transferrin-receptor-antibody-modified nanoparticles enable drug delivery across the blood–brain barrier (BBB). Eur J Pharm Biopharm. 2009;71(2):251–256.
   PubMed Web of Science ®Google Scholar
• Ulbrich K, Knobloch T, Kreuter J. Targeting the insulin receptor: nanoparticles for drug delivery across the blood-brain barrier (BBB). J Drug Target. 2011;19(2):125–132.
   PubMed Web of Science ®Google Scholar
• Betzer O, Shilo M, Opochinsky R, et al. The effect of nanoparticle size on the ability to cross the blood–brain barrier: an in vivo study. Nanomedicine (Lond). 2017;12(13):1533–1546.
   PubMed Web of Science ®Google Scholar
• Zhang B, Sun X, Mei H, et al. LDLR-mediated peptide-22-conjugated nanoparticles for dual-targeting therapy of brain glioma. Biomaterials. 2013;34(36):9171–9182.
   PubMed Web of Science ®Google Scholar
• Pinzón-Daza M, Garzón R, Couraud P, et al. The association of statins plus LDL receptor-targeted liposome-encapsulated doxorubicin increases in vitro drug delivery across blood-brain barrier cells. Br J Pharmacol. 2012;167(7):1431–1447.
   PubMed Web of Science ®Google Scholar
• Gromnicova R, Davies H, Sreekanthreddy P, et al. Glucose-coated gold nanoparticles transfer across human brain endothelium and enter astrocytes in vitro. PLoS One. 2013;8(12):e81043.
   PubMed Web of Science ®Google Scholar
• Anraku Y, Kuwahara H, Fukusato Y, et al. Glycaemic control boosts glucosylated nanocarrier crossing the BBB into the brain. Nat Commun. 2017;8(1):1001.
   PubMed Web of Science ®Google Scholar
• Tosi G, Badiali L, Ruozi B, et al. Can leptin-derived sequence-modified nanoparticles be suitable tools for brain delivery? Nanomedicine (Lond). 2012;7(3):365–382.
   PubMed Web of Science ®Google Scholar
• You L, Wang J, Liu T, et al. Targeted brain delivery of rabies virus glycoprotein 29-modified deferoxamine-loaded nanoparticles reverses functional deficits in Parkinsonian mice. ACS Nano. 2018;12(5):4123–4139.
   PubMed Web of Science ®Google Scholar
• Tosi G, Vilella A, Veratti P, et al. Exploiting bacterial pathways for BBB crossing with PLGA nanoparticles modified with a mutated form of diphtheria toxin (CRM197): in vivo experiments. Mol Pharm. 2015;12(10):3672–3684.
   PubMed Web of Science ®Google Scholar
• Kuo Y, Chung C. Transcytosis of CRM197-grafted polybutylcyanoacrylate nanoparticles for delivering zidovudine across human brain-microvascular endothelial cells. Colloids Surf B Biointerfaces. 2012;2012(91):242–249.
   Web of Science ®Google Scholar
• Ashizawa A, Steindler D. ET-61 Novel lipid nanoparticles for the delivery of nucleic acids to glioblastoma. Neuro Oncol. 2014;16(Suppl 5):v92.
   PubMed Web of Science ®Google Scholar
• Kreuter J, Shamenkov D, Petrov V, et al. Apolipoprotein-mediated transport of nanoparticle-bound drugs across the blood-brain barrier. J Drug Target. 2002;10(4):317–325.
   PubMed Web of Science ®Google Scholar
• Gaillard P. Case study: to-BBB’s G-Technology, getting the best from drug-delivery research with industry-academia partnerships. Ther Deliv. 2011;2(11):1391–1394.
   PubMedGoogle Scholar
• Gao H, Pang Z, Jiang X. Targeted delivery of nano-therapeutics for major disordersof the central nervous system. Pharm Res. 2013;30(10):2485–2498.
   PubMed Web of Science ®Google Scholar
• Malmo J, Sandvig A, Vårum K, et al. Nanoparticle mediated P-glycoprotein silencing for improved drug delivery across the blood-brain barrier: a siRNA-chitosan approach. PLoS One. 2013;8(1):e54182.
   PubMed Web of Science ®Google Scholar